Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2018
April 15, 2019 at 10:45 pm IST
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was CNY 0 compared to CNY 346.054 million a year ago. Sales was CNY 395.514 million compared to CNY 0 a year ago. Sales was CNY 395.514 million compared to CNY 346.054 million a year ago. Operating loss was CNY 28.807 million compared to operating Income of CNY 18.504 million a year ago. Net loss was CNY 29.439 million compared to net income of CNY 7.288 million a year ago. Basic loss per share from continuing operations was CNY 0.0286 compared to basic earnings per share from continuing operations of CNY 0.0071 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
